Home / Health / FDA Approves AbbVie's Once-Daily Parkinson's Pill
FDA Approves AbbVie's Once-Daily Parkinson's Pill
26 Sep
Summary
- AbbVie's new Parkinson's drug, Juvmo, received FDA approval.
- The drug, tavapadon, is administered as a once-daily pill.
- AbbVie acquired the drug through its $8.7 billion purchase of Cerevel Therapeutics.
In a significant development for Parkinson's disease patients, the U.S. Food and Drug Administration has granted approval to AbbVie's new once-daily oral medication. The drug, identified by the scientific name tavapadon and to be sold under the brand name Juvmo, targets adults grappling with Parkinson's disease. This condition is characterized by its progressive damage to the brain's control over movement, often manifesting as tremors, rigidity, and difficulties with balance.
The approval marks a key milestone for AbbVie, which gained access to tavapadon following its substantial $8.7 billion acquisition of Cerevel Therapeutics in 2023. This strategic move has now brought a new therapeutic option to the market, offering hope for improved management of Parkinson's symptoms. The once-daily pill format is expected to enhance patient adherence and convenience in managing this chronic neurological disorder.
